

29 November 2017

## Change of Company Secretary and CFO

In accordance with Listing Rule 3.16.1 **Recce Pharmaceuticals Limited (ASX:RCE) (Company)** gives notice that Mr Peter Williams is no longer Company Secretary and CFO.

Consistent with the Company's growing international interests, the following will support the Company from their respective independent legal and accountancy backgrounds.

Alistair McKeough, from Whittens & McKeough Pty Ltd Sydney has been appointed Company Secretary with effect from 29 November 2017. For the purposes of ASX Listing Rule 12.6, from 29 November 2017, Alistair McKeough is also the person responsible for communications between the Company and ASX.

The Company has also outsourced its CFO function to Pitcher Partners Sydney, with that relationship to be managed by Mr Justin Reynolds.

Recce's Executive Chairman Dr Graham Melrose thanks Mr Peter Williams for his contributions.

For further information please visit [www.recce.com.au](http://www.recce.com.au) or contact:

### Investor Relations

James Graham  
Executive Director  
Recce Pharmaceuticals Ltd  
Tel: +61 (02) 8075 4585

### Media (Australia)

Andrew Geddes  
CityPR  
Tel: +61 (02) 9267 4511

### Media (International)

Sue Charles/Gemma Harris  
Instinctif Partners  
Tel: +44 (0)20 7866 7860  
E: [recce@instinctif.com](mailto:recce@instinctif.com)

### About Recce Pharmaceuticals Limited

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as [RECCE® 327](#) has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results to date. Recce Pharmaceuticals has manufacturing facilities in Australia and clinical research partners in the USA. The Company has validated an automated process to manufacture its lead compound ahead of first-in-human clinical trials.

To receive the latest information on Recce Pharmaceuticals - [Subscribe here](#)

ENDS



ASX: RCE

**Head Office** Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

**R&D Centre - Perth** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (0)8 9253 9800 **F** +61 (0)8 9253 9899

**Washington Office** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA